Nurofena For Children Strawberr 100 mg per 5 ml Oral suspension
Clinical Summary
Quick overview from the medicine insert
Indication
Relief of fever, pain, and inflammation in children.
Dosage (summary)
Children: 20 mg/kg/day in divided doses. Adults: 400 mg initially, then 200-400 mg every 4 hours, max 1200 mg/day.
Onset of Action / Duration
Onset: 30 mins, Duration: 6-8 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in third trimester; not recommended during breastfeeding.
Key Drug Interactions
- Anticoagulants
- Lithium
- Digoxin
- Other NSAIDs
Contraindications
- Hypersensitivity to ibuprofen
- Heart failure
- Gastrointestinal ulceration
- Severe liver/renal impairment
- Children under 1 year
Common side effects
- Gastrointestinal bleeding
- Headache
- Nausea
- Skin rash
- Dizziness
Counselling Points
- Use lowest effective dose
- Monitor for GI symptoms
- Discontinue at first sign of rash
Serious warnings
- Risk of gastrointestinal perforation
- Cardiovascular risks
- Serious skin reactions
The Nurofena For Children Strawberr 100 mg per 5 ml Oral suspension professional information leaflet below is the property of Reckitt Benckiser Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
Clinical Particulars
Section 4 of the official insert — extracted exactly as issued, no alterations
4.1 Therapeutic indications
For the relief of symptoms of fever, pain and inflammation, associated with cold and flu, a sore throat, earache, headache, dental pain and minor aches and sprains.
4.2 Posology and method of administration
Use the lowest effective dose for the shortest possible duration of treatment. The dosage of NUROFENu00ae for Children STRAWBERRY is 20 mg/kg of body weight per day given in divided doses. Do not give to children under 12 months of age.
Children:
- Pain: Initial dose 5mg/kg body weight. A second dose of 5 mg/kg may be given after 2 hours if pain is not controlled, thereafter 5 mg/kg every 6 hours. A total dose of 20 mg/kg of body weight per day should not be exceeded.
- Fever: 5 mg/kg of body weight every 6 hours. A total dose of 20 mg/kg of body weight per day should not be exceeded. If pain persists for more than 3 days, a doctor should be consulted.
Adult: The initial dose is 400 mg (20 ml), then if necessary 200 mg or 400 mg (10 ml or 20 ml) every four hours. A total dose of 1 200 mg (60 ml) in any 24 hours should not be exceeded.
4.3 Contraindications
- Hypersensitivity to any of the ingredients of NUROFENu00ae for Children STRAWBERRY, including excipients (see COMPOSITION).
- Hypersensitivity to Ibuprofen, aspirin or any other non-steroidal anti-inflammatory medicine. Because of the possibility of cross-sensitivity due to structural relationships which exist among non-steroidal anti-inflammatory medicines, acute allergic reactions may be more likely to occur in patients who have exhibited allergic reactions to these compounds.
- Use of NUROFENu00ae for Children STRAWBERRY is contra-indicated in patients with heart failure.
- History of gastrointestinal perforation, ulceration or bleeding (PUBs) related to previous NSAIDs including NUROFENu00ae for Children STRAWBERRY.
- Active or history of recurrent ulcer/haemorrhage/perforations.
- Severe impairment of liver and renal function.
- Pregnancy in the third trimester (see HUMAN REPRODUCTION).
- Aspirin-induced nasal polyps associated with bronchospasm.
- Uncontrolled asthma.
- Children under the age of one year.
- Porphyria.
- Concomitant treatment with lithium (see INTERACTIONS).
- Concomitant treatment with digoxin (see INTERACTIONS).
4.4 Special warnings and precautions for use
The lowest effective dose for the shortest duration necessary to control symptoms should be used (see GI and cardiovascular risks below).
Cardiovascular and cerebrovascular effects: Caution is required in patients with a history of hypertension and/or heart failure as fluid retention and oedema have been reported in association with NUROFENu00ae for Children STRAWBERRY therapy. In view of the NUROFENu00ae for Children STRAWBERRYu2019s inherent potential to cause fluid retention, heart failure may be precipitated in some compromised patients. Caution is required in patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) and should only be treated with diclofenac after careful consideration.
Gastrointestinal effects: The risk of gastrointestinal perforation, ulceration or bleeding (PUBs) is higher with increasing doses of NUROFENu00ae for Children STRAWBERRY, in patients with a history of ulcers, and the elderly (see CONTRAINDICATIONS). Gastrointestinal bleeding, peptic ulceration or perforation which can be fatal, has been reported with all NSAIDs including NUROFENu00ae for Children STRAWBERRY at any time during treatment, with or without warning symptoms or a previous history of serious GI events.
Patients with a history of GI toxicity, particularly the elderly, should report any unusual abdominal symptoms (especially GI bleeding). When gastrointestinal bleeding or ulceration occurs in patients receiving NUROFENu00ae for Children STRAWBERRY, treatment with NUROFENu00ae for Children STRAWBERRY should be stopped.
DRESS: Drug Reaction with Eosinophillia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs such as NUROFENu00ae for Children STRAWBERRY. Some of these events have been fatal or life threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, haematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection. Eosinophillia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue NUROFENu00ae for Children STRAWBERRY and evaluate the patient immediately.
Dermatological effects: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Severe skin reaction such as acute generalised exanthematous pustulosis (AGEP) has been reported. NUROFENu00ae for Children STRAWBERRY should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.
Pregnancy: Regular use of NSAIDs such as NUROFENu00ae for Children STRAWBERRY during the third trimester of pregnancy, may result in premature closure of the foetal ductus arteriosus in utero, and possibly, in persistent pulmonary hypertension of the new-born. The onset of labour may be delayed and its duration increased.
Respiratory: Bronchospasm may be precipitated in patients suffering from or with a history of bronchial asthma or allergic disease.
Other NSAIDs: The use of NUROFENu00ae for Children STRAWBERRY with concomitant NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided (see INTERACTIONS).
SLE and mixed connective tissue disease: Systemic lupus erythematosus and mixed connective tissue disease, due to increased risk of aseptic meningitis (see SIDE EFFECTS).
Renal: There is a risk of renal impairment in dehydrated children and adolescents (see CONTRAINDICATIONS AND SIDE EFFECTS).
Hepatic: Hepatic dysfunction (see CONTRAINDICATIONS AND SIDE EFFECTS).
Elderly: The elderly have an increased frequency of adverse reactions to NSAIDs including NUROFENu00ae for Children STRAWBERRY, especially gastrointestinal perforation, ulceration and bleeding (PUBs) which may be fatal.
Complications with infections: Varicella can be at the origin of serious cutaneous and soft tissues infectious complications. NSAIDs such as NUROFENu00ae for Children STRAWBERRY increase the risk of worsening of these infections. Thus, it is advisable to avoid use of NUROFENu00ae for Children STRAWBERRY in case of varicella.
NUROFENu00ae for Children STRAWBERRY should be discontinued in patients who experience blurred or diminished vision, or changes in colour vision. Patients with collagen disease may be at increased risk of developing aseptic meningitis. NUROFENu00ae for Children STRAWBERRY can mask symptoms of infection, which may lead to delayed initiation of appropriate treatment and thereby worsening the outcome of the infection. This has been observed in bacterial community acquired pneumonia and bacterial complications to varicella. When this medicine is administered for pain or fever in relation to infection, monitoring of infection is advised. In non-hospital settings, the patient should consult a doctor if symptoms persist or worsen.
4.5 Interactions with other medicines
NUROFENu00ae for Children STRAWBERRY should be avoided in combination with:
- Other NSAIDs including cyclooxygenase-2 selective inhibitors: Concomitant use of two or more NSAIDs should be avoided as this may increase the risk of adverse effects (see WARNING AND SPECIAL PRECAUTIONS).
- Anti-coagulants: NUROFENu00ae for Children STRAWBERRY may enhance the effects of anti-coagulants, such as warfarin (see WARNING AND SPECIAL PRECAUTIONS).
- Anti-hypertensives (ACE inhibitors and Angiotensin II Antagonists) and diuretics: NUROFENu00ae for Children STRAWBERRY may diminish the effects of these medicines. Diuretics can increase the risk of nephrotoxicity of NUROFENu00ae for Children STRAWBERRY.
- Corticosteroids: increased risk of gastrointestinal ulceration or bleeding (see WARNING AND SPECIAL PRECAUTIONS).
- Anti-platelet medicines and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding (see WARNINGS AND SPECIAL PRECAUTIONS).
- Digoxin: NUROFENu00ae for Children STRAWBERRY may exacerbate cardiac failure, reduce renal function and increase plasma digoxin levels.
- Lithium: there is evidence for potential increases in plasma levels of lithium (see CONTRAINDICATIONS).
- Methotrexate: there is a potential for an increase in plasma levels of methotrexate.
- Ciclosporin: increased risk of nephrotoxicity.
- Mifepristone: NUROFENu00ae for Children STRAWBERRY should not be used for 8-12 days after mifepristone administration as NUROFENu00ae for Children STRAWBERRY can reduce the effect of mifepristone.
- Tacrolimus: possible increased risk of nephrotoxicity when NUROFENu00ae for Children STRAWBERRY are given with tacrolimus.
- Zidovudine: increased risk of haematological toxicity when NUROFENu00ae for Children STRAWBERRY is given with zidovudine. There is evidence of an increased risk of haemarthroses and haematoma in haemophiliacs receiving concurrent treatment with zidovudine and NUROFENu00ae for Children STRAWBERRY.
- Quinolone antibiotics: animal data indicate that NSAIDs including NUROFENu00ae for Children STRAWBERRY can increase the risk of convulsions associated with quinolone antibiotics. Patients taking NUROFENu00ae for Children STRAWBERRY and quinolones may have an increased risk of developing convulsions.
4.6 Fertility, pregnancy and lactation
Pregnancy: NUROFENu00ae for Children STRAWBERRY should be avoided during the first and second trimesters of pregnancy. During the third trimester, the use of NUROFENu00ae for Children STRAWBERRY is contraindicated (see CONTRAINDICATIONS).
Lactation: NUROFENu00ae for Children STRAWBERRY is not recommended during breastfeeding as ibuprofen is excreted in breastmilk in very low concentrations.
Fertility: NUROFENu00ae for Children STRAWBERRY may impair female fertility by an effect of ovulation. This is reversible upon withdrawal of treatment.
4.7 Effects on ability to drive and use machines
No adverse effects known.
4.8 Undesirable effects
The following side-effects have been reported:
Table 1: Report side effects for NUROFENu00ae for Children STRAWBERRY
| System organ class | Frequencies | Adverse event |
|---|---|---|
| Blood and lymphatic system disorders | Less frequent | Haematopoietic disorders (anaemia, leucopenia, thrombocytopenia, pancytopenia, agranulocytosis). First signs are: fever, sore throat, superficial mouth ulcers, flu-like symptoms, severe exhaustion, unexplained bleeding and bruising. |
| Immune system disorders | Less frequent | Hypersensitivity reactions consisting of urticaria and pruritus. Severe hypersensitivity reactions. Symptoms could be facial, tongue and laryngeal swelling, dyspnoea, tachycardia, hypotension (anaphylaxis, angioedema or severe shock). |
| Not known | Respiratory tract reactivity comprising asthma, aggravated asthma, bronchospasm or dyspnoea. | |
| Nervous system disorders | Less frequent | Headache, aseptic meningitis. |
| Cardiac disorders | Not known | Cardiac failure and oedema. |
| Vascular disorders | Not known | Hypertension. |
| Gastrointestinal disorders | Less frequent | Abdominal pain, nausea, dyspepsia, diarrhoea, flatulence, constipation and vomiting, peptic ulcer, perforation or gastrointestinal haemorrhage, melaena, haematemesis, sometimes fatal, particularly in the elderly. Ulcerative stomatitis, gastritis. |
| Not known | Exacerbation of colitis and Crohn's disease. | |
| Hepatobiliary disorders | Less frequent | Liver disorders. |
| Skin and subcutaneous tissue disorders | Less frequent | Various skin rashes, severe forms of skin reactions such as bullous reactions including Stevens-Johnson syndrome, erythema multiforme and toxic epidermal necrolysis can occur. |
| Not known | DRESS syndrome, acute generalised exanthematous pustulosis (AGEP), photosensitivity reactions. | |
| Renal and urinary disorders | Less frequent | Acute renal failure, papillary necrosis, especially in long-term use, associated with increased serum urea and oedema. |
| Not known | Renal insufficiency. |
4.9 Overdose
Symptoms: In children, the ingestion of more than 400 mg/kg of ibuprofen may cause symptoms. In adults, the dose response effect is less clear cut. The half-life in overdose is 1.5 u2013 3 hours. The most likely symptoms of over dosage are pain in upper, middle region of the stomach and nausea, vomiting and dizziness, tinnitus, headache, diarrhoea, gastrointestinal bleeding. In more serious poisoning, drowsiness, excitation, coma convulsions, metabolic acidosis prolongation of prothrombin time/INR, renal failure, liver damage, and asthma exacerbation may occur.
Management: Management should be symptomatic and supportive and include the maintenance of clear airway and monitoring of cardiac and vital signs until stable. Consider oral administration of activated charcoal if the patient presents within 1 hour of ingestion of a potentially toxic amount. If frequent or prolonged, convulsions should be treated with intravenous diazepam or lorazepam. Give bronchodilators for bronchospasm.